SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
sysiphus
TucsonAZMav
zevenhuizen
To: dorightbythem who wrote (38508)1/7/2017 4:21:29 PM
From: bobbseytwins20013 Recommendations  Read Replies (4) of 63291
 
It is an amazing phenomena that in investing the crowd only sees the obvious solution AFTER it happens, because they are totally focused on what has happened in the past. The assumption here is that the Goldenberg's have been sitting around doing nothing in the face of venBio's challenge, and have not considered the possibility of losing operational control of IMMU, and that they are not concerned, and their ample stockholdings mean nothing to them as long as they collect their generous salaries this year. In addition the assumption is that Greenhill [GHC] is pursuing a licensing deal for 132, when their stated existential purpose prominent on the GHC website would beg to differ. Also being ignored is that this is the first time in the company's long history that being published in an established medical journal has been publicized in advance, indicating real confidence in 132, and that almost all of the required 100 phase 2 patients have already been observed by their doctors in advance of the Jan 18 "R&D" presentation. IMMU investors have constantly been misdirected, shocked and caught unawares for years. So what are we missing this time?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News